CNS Outcomes in ALK Fusion Positive NSCLC Patients with BM Who Received Alectinib with or without Local Therapy

被引：0
|
作者：
Miao, E. [1 ]
Lebow, E. S. [2 ]
Eichholz, J. [3 ]
Flynn, J.
Zhang, Z. [3 ,4 ]
Hubbeling, H. G.
Beal, K.
Moss, N. S. [5 ]
Yu, K. [3 ]
Yang, J. T. [3 ]
Kelly, D. W. [3 ]
Gomez, D. R. [2 ]
Rimner, A. [2 ]
Drilon, A. [5 ]
Imber, B. S. [6 ]
Pike, L. R. G. [3 ]
机构：
[1] Albert Einstein Coll Med, Bronx, NY 10467 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Neurosurg, 1275 York Ave, New York, NY 10021 USA
[6] Mem Sloan Kettering Canc Ctr, Brain Metastasis Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2022年 / 114卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2131
引用
收藏
页码：E59 / E60
页数：2
相关论文
共 50 条
  • [41] Response to "Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence"
    Groenland, Stefanie L.
    Geel, Dieuwertje R.
    Beijnen, Jos H.
    Smit, Egbert F.
    Huitema, Alwin D. R.
    Steeghs, Neeltje
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (05) : 1164 - 1164
  • [42] Real-world comparative effectiveness of 1L alectinib (ALC) vs crizotinib (CRZ) in patients (pts) with ALK plus advanced NSCLC with or without baseline CNS metastases (mets)
    Krebs, M. G.
    Lin, J. J.
    Pal, N.
    Polito, L.
    Trinh, H. T. L.
    Hilton, M. M. S. M.
    Smoljanovic, V.
    Kurtsikidze, N.
    Archer, V.
    Zhang, Q.
    ANNALS OF ONCOLOGY, 2021, 32 : S959 - S959
  • [43] Alectinib exposure-response (ER) in ALK-inhibitor naive ALK-positive NSCLC patients: Pooled analysis across phase III studies.
    Smart, Kevin
    Hsu, Joy C.
    Jaminion, Felix
    Guerini, Elena
    Shaw, Alice Tsang
    Zhou, Caicun
    Mok, Tony S. K.
    Bordogna, Walter
    Frey, Nicolas
    Morcos, Peter N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] Outcomes of Early Stage ALK-positive NSCLC patients in a Real-World Cohort
    Schmid, S.
    Chotai, S.
    Cheng, S.
    Zhan, L.
    Balaratnam, K.
    Khan, K.
    Patel, D.
    Brown, M. C.
    Xu, W.
    Moriarty, P.
    Kaidanovich-Beilin, O.
    Shepherd, F. A.
    Sacher, A.
    Leighl, N.
    Bradbury, P.
    Liu, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S908 - S909
  • [45] Real-world-outcomes for ALK positive advanced NSCLC patients treated in South Yorkshire
    Sheehan, Roseleen
    Barakat, Dina
    Bhakta, Jamie
    Meehan, Danielle
    Shah, Farah
    Tobin, Jonathan
    Das, Tathagata
    Grassby, Rebekah
    Bates, Emma
    Danson, Sarah
    Fisher, Patricia
    Hatton, Matthew
    Mathew, Tony
    Taylor, Fiona
    Young, Robin
    Lee, Caroline
    LUNG CANCER, 2021, 156 : S39 - S39
  • [46] Alectinib in ALK-Rearranged NSCLC Patients Following Crizotinib. Final Results and Biological Outcomes - Phase II ATALK Study
    Cortot, A.
    Escande, F.
    Gervais, R.
    Greillier, L.
    Corre, R.
    Veillon, R.
    Ionescu, M.
    Felicio, H.
    Pau, D.
    Gregoire, V.
    Girard, N.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S658 - S658
  • [47] Clinical Outcomes, Long-Term Survival and Toleration With Sequential Therapy of First-Line Crizotinib Followed by Alectinib in ALK plus NSCLC
    Zou, Z.
    Xing, P.
    Hao, X.
    Zhang, C.
    Ma, K.
    Shan, L.
    Song, X.
    Li, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1091 - S1092
  • [48] Survival Benefit of Sequential Therapy in ALK Positive Olioprogressive NSCLC Patients After Crizotinib Resistance
    Xu, H.
    Ma, D.
    Yang, G.
    Li, J.
    Hao, X.
    Xing, P.
    Yang, L.
    Wang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S503 - S503
  • [49] Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastases
    Zhang, Qing
    Lin, Jessica J.
    Pal, Navdeep
    Polito, Letizia
    Trinh, Huong
    Hilton, Magalie
    Smoljanovi, Vlatka
    Kurtsikidze, Nino
    Archer, Venice
    Krebs, Matthew G.
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (04):
  • [50] Entrectinib in Patients with ROS1-Positive NSCLC or NTRK Fusion-Positive Solid Tumors with CNS Metastases
    Paz-Ares, L.
    Dziadziuszko, R.
    Drilon, A.
    John, T.
    Krebs, M.
    Demetri, G.
    Shaw, A.
    Siena, S.
    Wolf, J.
    Farago, A.
    Simmons, B.
    Ye, C.
    Huang, X.
    Doebele, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S305 - S305
12345